Cancer immunotherapy represents a growing research field and is emerging as a powerful weapon for cancer treatment. It has been hailed as the most promising advancement for the treatment of cancer in recent years. It’s an exhilarating time as immuno-oncology research accelerates at a rapid pace and, whilst the progress to date has been uplifting, there is still much to decipher on how this complex approach will work best.
This series of podcasts from Clarivate Analytics aims to disseminate the scientific landscape in immuno-oncology to professionals in the field, with comprehensive insights from our industry experts, presented in concise and digestible episodes.
Register for our latest Episodes on the ONCOLOGY TALKS iTunes page.
Dr. Joshua Schnell is a Director at Clarivate Analytics, with expertise in science planning and assessment, the evaluation of research and development (R&D) programs, and in science and technology (S&T) policy, and helps to set the strategic direction of Clarivate solutions. Previously, he oversaw a team of analysts conducting program evaluations of research and training programs and developing tools for data-driven science management. Before joining Clarivate Analytics, Dr. Schnell directed the analytics group at a science management start-up in the Washington DC area, worked in research administration at Northwestern University, and was an S&T Policy Graduate Fellow at the US National Academies of Science. He holds a PhD from Northwestern University.View Profile >
Dr. Richard K. Harrison is the Chief Scientific Officer at Clarivate Analytics. He has over 30 years of experience in the life sciences industry. His career has focused on all aspects of pre-clinical drug discovery. During this time he has held positions of increasing responsibility at Aventis, Merck, DuPont and Wyeth Pharmaceuticals where he delivered numerous clinical candidates and worked on several marketed drugs. In addition, he served as a founding scientist in two successful venture funded computational and structure based drug design companies. Dr. Harrison has authored over 40 peer reviewed publications and book chapters in all areas of drug discovery and has presented over 50 invited lectures on these subjects. He earned his Ph.D. in Biophysical Chemistry and Enzymology and currently serves as an adjunct professor at several universities.View Profile >
In her role as Solutions Specialist, Amy Braden consults with Clarivate Analytics customers working in government and academic organizations, mapping client needs to product and service offerings. Amy has over 10 years of experience working in the education sector in various roles. Prior to joining Clarivate Analytics, she worked in the Hahnemann Health Sciences Library at Drexel University while completing a Master’s degree in Library and Information Science.View Profile >
Chris Willis began his career in science as an undergrad at University of Delaware upon receiving a Howard Hughes Medical Institute scholarship to train in a structural biology lab. His interest in protein structure/function took him to graduate school at University of Maryland School of Medicine where he received his PhD in Biochemistry and Molecular Biology. He conducted his dissertation research in a physiology lab and focused on interactions that regulate proper calcium signaling and muscle contraction. Upon graduating, he moved into the field of oncology and as a postdoc at the Kimmel Cancer Center, he studied anti-angiogenic mechanisms in tumors using gene expression profiling. Throughout his academic career, Chris published papers that are part of the Web of Science before starting at Thomson Reuters (Now Clarivate Analytics) in 2012 as a solution scientist supporting the discovery, translational and pre-clinical solutions. Currently he manages the global team of scientists who specialize in combination knowledge and data driven approaches to translational informatic applications.View Profile >
Di Cross is the Director of Research Analytics for the Research Data Science & Evaluation team in Clarivate Analytics. She and her team conduct program evaluation, bibliometric analysis, research assessment & benchmarking, and portfolio analysis for funders and producers of scientific research worldwide.View Profile >
As a Strategic Account Manager, Bertrand Sautier is responsible for the management and growth of Clarivate Analytics IP accounts in Europe. Based in London, he joined Clarivate Analytics in 2013 as a Solution Consultant, responsible for the design and delivery of fee-based technology consulting projects. Prior to joining Clarivate Analytics, he worked in the patent litigation department at ReedSmith LLP in Paris and held various legal roles at Danone and Salomon. Bertrand holds a Master in Law from Grenoble Faculty of Law, is a graduate from Essec Business School and holds an LLM from King’s College London. Bertrand is also an Intellectual Property Lecturer and Academic. He is currently finishing his PhD in Private Law at the Grenoble Alpes University.View Profile >
Jack Hopwood is an Intellectual Property Consultant at Clarivate Analytics. In his role he works closely with clients to help them better understand their technical and competitive environment by delivering findings that support more informed business decisions relating to their IP Strategy. His specialties include global patent research and analytics, particularly in the Life Sciences sector. He also has a Master’s in Cancer Research from the University of Kent, where he completed his thesis titled: “The Effect of Overexpression of the Oncogene EeF1α on Chemotherapeutic Toxicity.”View Profile >
Anette Breindl, Ph.D. has been with BioWorld since 2004, covering science, medicine, business, and the intersection of the three, and is currently a senior science editor. She has also worked as a freelance writer for U.S. and German publications, and co-authored several peer-reviewed papers. Anette earned a Ph.D. from the Leibniz Institute for Neurobiology in Magdeburg, Germany, and a BA from the University of California at Berkeley. Her stories “To drug the undruggables, first think the unthinkable” and "Embryonic stem cells: Individual medicine – but with two individuals” have won awards for scientific writing or technical reporting from the Specialized Information Publishers Association.View Profile >
Peter Winter is a science journalist based in Ottawa, Canada. His early career spanned cancer research and the pharmaceutical industry before devoting his career to science writing and editing, specializing in the biotechnology and life sciences sectors. He has been writing about and analyzing the progress of the global biotech industry since the early 1980s. He is currently editor of BioWorld Insight, a weekly news service that tracks the financial and business trends of the biopharmaceutical industry. He received his undergraduate BSc degree from the University of London and is the recipient of the Science Journalism Laureate Award from Purdue University that recognizes outstanding global science communicators.View Profile >